CoChat

Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background/aims Primary biliary cirrhosis (PBC) is an autoimmune disease of the liver with inflammation of small and middle-sized bile ducts. Serum lipids are frequently elevated, but the use of a lipid lowering drug therapy in PBC is still a matter of debate. Application of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in hypercholesterolemic PBC patients was therefore the subject of the present study. Methods Six female patients (aged 46.5 (32-61) years; median (range)) were treated with the HMG-CoA reductase inhibitor simvastatin (5 or 20 mg/day). Levels of serum total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were determined prior to and after 2 months of treatment. Concentrations of serum markers of cholestasis, antimitochondrial antibodies (AMA), and immunoglobulins A, G and M were also assessed. Results Simvastatin significantly (P Conclusions The lipid lowering potency of the HMG-CoA reductase inhibitor simvastatin was confirmed in hypercholesterolemic patients with PBC. The drug might also prove useful as modulator of cholestasis and of immune response in this disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0168-8278(02)00006-5

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 33 references

Cited by

See all 97

Metadata

Authors
Ritzel, U., Leonhardt, U., Näther, M., Schäfer, G., Armstrong, V. W., & Ramadori, G.
Affiliations
  • Universitätsmedizin Göttingen (DE)
  • University of Göttingen (DE)
Corresponding author
Leonhardt, Urs
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2002-04
Volume
36
Issue
4
Pages
454-458
ISSN
0168-8278 (ISSN-L)
OpenAlex
W1969611494
Cited by
94
References
32
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2022: 2 · 2020: 2 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 1 · 2015: 5 · 2014: 3 · 2013: 6 · 2012: 3
FWCI
2.60
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • GRO (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
simvastatin, primary biliary cirrhosis, statins, serum lipids, hypercholesterolemia, LDL cholesterol, HDL cholesterol, total cholesterol, alkaline phosphatase, gamma-glutamyl transferase, antimitochondrial antibodies, immunoglobulin M, immunoglobulins, lipid-lowering therapy
MeSH terms
Adult, Alkaline Phosphatase, Hypolipidemic Agents, Cholesterol, Female, gamma-Glutamyltransferase, Humans, Immunoglobulin M, Lipids, Cholesterol, LDL, Liver Cirrhosis, Biliary, Middle Aged, Biomarkers, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. https://app.cochat.ai/papers/10.1016/s0168-8278(02)00006-5
The paper
Ritzel, U., Leonhardt, U., Näther, M., Schäfer, G., Armstrong, V. W., & Ramadori, G. (2002). Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(02)00006-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.